|
Federal
Register Notices > Manufacturers 2008
>
Cedarburg Pharmaceuticals, Inc.
FR Doc E8-26145[Federal Register: November 3, 2008 (Volume 73, Number 213)]
[Notices] [Page 65404] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03no08-74]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on July 15, 2008, Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug
Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of
controlled substances listed in schedules I and II:
|
Drug
|
Schedule
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Remifentanil (9739)
|
II
|
|
Sufentanil (9740)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to manufacture the listed controlled substances in bulk for
distribution to its customers.
Any other such applicant, and any person who is presently registered with DEA
to manufacture such substances, may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate,
to the Drug Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than January 2, 2009.
Dated: October 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-26145 Filed 10-31-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|